Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current Deffered RevenuePayablesPreferred Stock LiabilitiesPrepaid AssetsRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Drugs Made In America Acquisition (DMAA) Common Equity (2024 - 2025)

Drugs Made In America Acquisition filings provide 2 years of Common Equity readings, the most recent being -$7.3 million for Q4 2025.

  • Quarterly Common Equity fell 2866.77% to -$7.3 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was -$7.3 million through Dec 2025, down 2866.77% year-over-year, with the annual reading at -$7.3 million for FY2025, 2866.77% down from the prior year.
  • Common Equity hit -$7.3 million in Q4 2025 for Drugs Made In America Acquisition, up from -$7.3 million in the prior quarter.
  • Across five years, Common Equity topped out at -$244845.0 in Q4 2024 and bottomed at -$7.3 million in Q3 2025.